Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2023 Aug 1.

Published in final edited form as: Lancet Oncol. 2022 Jul 7;23(8):1009–1020. doi: 10.1016/S1470-2045(22)00369-2

Figure 2. — Panel A shows Kaplan-Meier estimates of progression-free survival (based on blinded independent central review) with a median PFS of 1.9 mo in nira/nivo and PFS 8.1 mo in nira/ipi. Panel B shows Kaplan Meier estimates of overall survival with a median OS of 14.0 mo in nira/nivo and 17.3 mo in nira/ipi.

Figure 2. — Panel A shows Kaplan-Meier estimates of progression-free survival (based on blinded independent central review) with a median PFS of 1.9 mo in nira/nivo and PFS 8.1 mo in nira/ipi. Panel B shows Kaplan Meier estimates of overall survival with a median OS of 14.0 mo in nira/nivo and 17.3 mo in nira/ipi.